Himalaya Nutravedics India IPO- Company Analysis
Himalaya Nutravedics India IPO under the SME IPO category is a book build issue of Rs. 26.50 Cr by Himalaya Nutravedics India Limited, which carries out third-party contract manufacturing for other Ayurvedic and nutraceutical businesses in addition to manufacturing, marketing, and distributing Ayurvedic and nutraceutical formulations in India. Its products come in a variety of dosage forms, such as tablets, liquid orals, hard and soft gelatin capsules, and medicated oils.
The products address a variety of therapeutic and wellness topics, including immunity, women's wellbeing, diabetic control, pain management, gut health, and cardiac and metabolic fitness.
Himalaya Nutravedics uses a hybrid business approach that combines contract production with its own branded products. The company's third-party manufacturing division offers formulation, manufacturing, packing, and delivery services in accordance with customer specifications, while its own-brand division creates, produces, and sells Ayurvedic and nutraceutical goods.
Himalaya Nutravedics India IPO Details
The Himalaya Nutravedics India IPO date of opening is 22 Sep 2026; its initial public offering will end on 24 Sep, IPO allotment on Sep 25 and refund initiation on Sep 28, 2026.
The Rs. 26.50 crore new SME IPO comprises a wholly fresh issue of 25 lakh shares.
The Himalaya Nutravedics India IPO listing date (expected) might be Tuesday, Sep 29, 2026, and the listing on the BSE and SME.
The Himalaya Nutravedics India IPO price band is Rs. 100 to Rs. 106.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
Sep 22, 2026 |
|
IPO Closing Date |
Sep 24, 2026 |
|
IPO Allotment Date |
Sep 25, 2026 |
|
Refund Initiation |
Sep 28, 2026 |
|
IPO Listing Date |
Sep 29, 2026 |
Click to open demat account and apply for the IPO.
Company Financials
(Amount in Cr)
|
Particulars |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Assets |
24.42 |
10.82 |
6.09 |
|
Total Income |
43.12 |
21.00 |
14.43 |
|
Profit After Tax |
7.39 |
2.23 |
0.43 |
|
EBITDA |
8.10 |
2.99 |
0.94 |
|
Net Worth |
16.38 |
6.75 |
1.34 |
|
Reserves and Surplus |
10.07 |
2.76 |
0.53 |
|
Total Borrowing |
5.13 |
1.76 |
3.24 |
Cash Flows
(Amount in Lac)
|
Net Cash Flow |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Net Cash Flow Operating Activities |
(383.44) |
(139.11) |
(55.10) |
|
Net Cash Flow Investing Activities |
(5.79) |
(22.60) |
(109.80) |
|
Net Cash Flow Financing Activities |
527.05 |
143.88 |
184.24 |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The Company desires to use the Net Proceeds from the Issue to fulfill its following goals:
-
Funding Working Capital Requirements. ~ Rs. 13.75 Cr.
-
Business Development and Digital Marketing Activities. ~ Rs. 7.50 Cr.
-
General Corporate Purposes.
Listed Peers of Himalaya Nutravedics India Ltd.
|
Name of the Company |
Face Value |
EPS (Basic) (₹) |
P/E |
|
Jeena Sikho Lifecare Limited |
2 |
17.84 |
28.75 |
|
Sandu Pharmaceuticals Limited |
10 |
1.83 |
20.62 |
Valuation
|
KPI |
Value (Mar 31, 2026) |
|
ROE |
63.87% |
|
ROCE |
36.41% |
|
Debt/Equity |
0.31 |
|
RoNW |
45.12% |
|
PAT Margin |
17.16% |
|
EBITDA Margin |
18.82% |
Evaluation of P/E Ratio
Considering the period ended on FY 2026 with an EPS of Rs. 12.05 from the last year, the resulting P/E ratio is 8.79x.
|
Valuation Metric |
Pre IPO |
Post IPO |
|
EPS (₹) |
EPS (₹) |
11.72 |
|
P/E (x) |
P/E (x) |
9.04 |
Explore the Quanto Agroworld IPO.
IPO's Strengths
-
Geographical spread across India.
-
Long-standing connections with suppliers and clients.
-
Integrated production capabilities for many dosages.
-
Physician acceptability is backed by product effectiveness.
IPO's Weaknesses
-
Incorporated in 2022, its shorter operating history may constrain institutional tie-ups and prescriber loyalty compared to established peers.
-
Primary reliance on doctor-led and pharmacy-based channels limits direct-to-consumer reach and e-commerce penetration.
-
Operating in AYUSH and nutraceutical segments requires continuous adherence to evolving FSSAI, AYUSH, and advertising regulations.
Himalaya Nutravedics India IPO GMP
Himalaya Nutravedics India IPO GMP today has not started yet as of 21 September 2026, while writing this information.
Himalaya Nutravedics India IPO Summary
|
IPO Opening & Closing Date |
22 Sep, 2026 to 24 Sep, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 100 to Rs. 106 per Share. |
|
Lot Size |
1200 Shares |
|
Issue Size |
24,99,600 Shares (Rs. 26 Cr) |
|
Offer for Sale |
- |
|
Fresh Issue |
23,73,600 Shares (Rs. 25 Cr) |
|
Market Makers |
1,26,000 Shares (Rs. 1 Cr) |
|
Issue Type |
Bookbuild Issue |
|
Registrar |
Kfin Technologies Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (2400 Shares) for Rs. 2,54,400, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (3600 Shares) for Rs. 3,81,600.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Himalaya Nutravedics India IPO Allotment Status
To check the Himalaya Nutravedics India IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Himalaya Nutravedics India Ltd.
-
Rohit Asawa
-
Divya Asawa
-
Chanda Asawa
-
Rama Raju Penmatsa
|
Pre-Issue Promoter Shareholding |
95.14% |
|
Post-Issue Promoter Shareholding |
68.13% |
IPO Lead Managers
- Nirbhay Capital Services Pvt. Ltd.
Dividend Policy
The company has not paid a dividend during the last three FYs.
Conclusion
Himalaya Nutravedics India IPO offers exposure to the growing Ayurvedic and nutraceutical sector, supported by strong revenue growth, profitability, and healthy return ratios. However, negative operating cash flows, a short operating history, and regulatory dependence remain key risks investors should consider before applying.
Other Related Blogs:-
Manika Plastech IPO
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
Read the company prospectus and download the DRHP.
Click Here To Stay Updated With The Upcoming IPOs.
DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.
